Original ResearchBevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Keywords: بسته لیتکسل هفتگی; Bevacizumab; Metastatic breast cancer; Predictive; Biomarker; Double-blind; VEGF-A; Weekly paclitaxel; Prospective;